insulin monotherapy

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27

In patients with NAFLD and diabetes, insulin use alone was not significantly associated with the risk of hepatocellular carcinoma compared with no diabetes medication.

Effect: null; HR 1.05; CI: 95% CI 0.88-1.27